B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 7.263 NOK 1.38% Market Closed
Market Cap: 294.9m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Intrinsic Value

BGBIO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one BGBIO stock under the Base Case scenario is 0.195 NOK. Compared to the current market price of 7.263 NOK, Bergenbio ASA is Overvalued by 97%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BGBIO Intrinsic Value
0.195 NOK
Overvaluation 97%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
Bergenbio ASA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BGBIO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BGBIO?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Bergenbio ASA

Provide an overview of the primary business activities
of Bergenbio ASA.

What unique competitive advantages
does Bergenbio ASA hold over its rivals?

What risks and challenges
does Bergenbio ASA face in the near future?

Summarize the latest earnings call
of Bergenbio ASA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bergenbio ASA.

Provide P/S
for Bergenbio ASA.

Provide P/E
for Bergenbio ASA.

Provide P/OCF
for Bergenbio ASA.

Provide P/FCFE
for Bergenbio ASA.

Provide P/B
for Bergenbio ASA.

Provide EV/S
for Bergenbio ASA.

Provide EV/GP
for Bergenbio ASA.

Provide EV/EBITDA
for Bergenbio ASA.

Provide EV/EBIT
for Bergenbio ASA.

Provide EV/OCF
for Bergenbio ASA.

Provide EV/FCFF
for Bergenbio ASA.

Provide EV/IC
for Bergenbio ASA.

Show me price targets
for Bergenbio ASA made by professional analysts.

What are the Revenue projections
for Bergenbio ASA?

How accurate were the past Revenue estimates
for Bergenbio ASA?

What are the Net Income projections
for Bergenbio ASA?

How accurate were the past Net Income estimates
for Bergenbio ASA?

What are the EPS projections
for Bergenbio ASA?

How accurate were the past EPS estimates
for Bergenbio ASA?

What are the EBIT projections
for Bergenbio ASA?

How accurate were the past EBIT estimates
for Bergenbio ASA?

Compare the revenue forecasts
for Bergenbio ASA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bergenbio ASA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bergenbio ASA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bergenbio ASA compared to its peers.

Compare the P/E ratios
of Bergenbio ASA against its peers.

Discuss the investment returns and shareholder value creation
comparing Bergenbio ASA with its peers.

Analyze the financial leverage
of Bergenbio ASA compared to its main competitors.

Show all profitability ratios
for Bergenbio ASA.

Provide ROE
for Bergenbio ASA.

Provide ROA
for Bergenbio ASA.

Provide ROIC
for Bergenbio ASA.

Provide ROCE
for Bergenbio ASA.

Provide Gross Margin
for Bergenbio ASA.

Provide Operating Margin
for Bergenbio ASA.

Provide Net Margin
for Bergenbio ASA.

Provide FCF Margin
for Bergenbio ASA.

Show all solvency ratios
for Bergenbio ASA.

Provide D/E Ratio
for Bergenbio ASA.

Provide D/A Ratio
for Bergenbio ASA.

Provide Interest Coverage Ratio
for Bergenbio ASA.

Provide Altman Z-Score Ratio
for Bergenbio ASA.

Provide Quick Ratio
for Bergenbio ASA.

Provide Current Ratio
for Bergenbio ASA.

Provide Cash Ratio
for Bergenbio ASA.

What is the historical Revenue growth
over the last 5 years for Bergenbio ASA?

What is the historical Net Income growth
over the last 5 years for Bergenbio ASA?

What is the current Free Cash Flow
of Bergenbio ASA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bergenbio ASA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bergenbio ASA

Current Assets 218.3m
Cash & Short-Term Investments 200.1m
Receivables 12.9m
Other Current Assets 5.3m
Non-Current Assets 220k
PP&E 221k
Other Non-Current Assets -1k
Current Liabilities 43.2m
Accounts Payable 8.6m
Other Current Liabilities 34.6m
Efficiency

Earnings Waterfall
Bergenbio ASA

Revenue
521k NOK
Operating Expenses
-162.7m NOK
Operating Income
-162.2m NOK
Other Expenses
6.8m NOK
Net Income
-155.4m NOK

Free Cash Flow Analysis
Bergenbio ASA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

BerGenBio reported progress in its study of bemcentinib for non-small cell lung cancer, targeting STK11 mutations. With a consistent quarterly burn rate of NOK 40 million, the company anticipates cash to last until mid-2025, with a current cash position of NOK 200 million. Positive recommendations have been received for the safety of two dose levels moving into the Phase IIa trial, aimed at enrolling 40 patients. The firm forecasts significant improvements in progression-free survival from 5 to over 8 months and overall survival up to 14-15 months. Updates are expected later this year and early 2025, keeping investor interest high.

What is Earnings Call?
Fundamental Scores

BGBIO Profitability Score
Profitability Due Diligence

Bergenbio ASA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional ROIC
Exceptional 1-Year Revenue Growth
Negative 3-Years Revenue Growth
36/100
Profitability
Score

Bergenbio ASA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

BGBIO Solvency Score
Solvency Due Diligence

Bergenbio ASA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
78/100
Solvency
Score

Bergenbio ASA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BGBIO Price Targets Summary
Bergenbio ASA

Wall Street analysts forecast BGBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BGBIO is 20.4 NOK with a low forecast of 5.05 NOK and a high forecast of 39.9 NOK.

Lowest
Price Target
5.05 NOK
30% Downside
Average
Price Target
20.4 NOK
181% Upside
Highest
Price Target
39.9 NOK
449% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BGBIO?

Click here to dive deeper.

Dividends

Bergenbio ASA
does not pay dividends
Shareholder Yield

Current shareholder yield for BGBIO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Bergenbio ASA

Country

Norway

Industry

Biotechnology

Market Cap

283.9m NOK

Dividend Yield

0%

Description

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

Contact

HORDALAND
Bergen
Jonas Lies vei 91
+4755961159.0
www.bergenbio.com

IPO

2017-04-07

Employees

46

Officers

Chief Executive Officer
Mr. Martin Olin
Chief Financial Officer
Mr. Rune Skeie
Chief Medical Officer
Ms. Cristina Oliva M.D.
Head of IR
Graham Morell
Chief Business Officer
Ms. Gayle M. Mills M.B.A
Medical Director
Dr. Akil Jackson

See Also

Discover More
What is the Intrinsic Value of one BGBIO stock?

The intrinsic value of one BGBIO stock under the Base Case scenario is 0.195 NOK.

Is BGBIO stock undervalued or overvalued?

Compared to the current market price of 7.263 NOK, Bergenbio ASA is Overvalued by 97%.

Back to Top